Market research reports, consulting: Global Market Insights Inc.
We use cookies to enhance user experience. (Privacy Policy)

Injectable Cytotoxic Drugs Market Share

Report ID: GMI9610
   |
Published Date: May 2024
 | 
Report Format: PDF

Download free sample

Injectable Cytotoxic Drugs Market Share

The injectable cytotoxic drugs industry is fragmented as these drugs are off-patent and are commercially available as a generic. Although major market players hold significant influence, smaller companies and research institutions also play a vital role in advancing and bringing new cytotoxic drugs to the market. Established players have extensive pipelines, substantial research capabilities, and established partnerships with other pharmaceutical companies. Small companies are majorly involved in the researching and developing new targeted small molecules/combination therapies focusing on niche areas or specific type of cancer, which has contributed to the overall diversity in the market.
 

Injectable cytotoxic drugs Market Companies

Prominent players operating in the market include:

  • Abbvie Inc
  • Accord Healthcare
  • Amgen, Inc.
  • Baxter International Inc. 
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Johnson and Johnson Services Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Authors: Mariam Faizullabhoy, Gauri Wani
Frequently Asked Question(FAQ) :
How much is the injectable cytotoxic drugs market worth?
The global market size for injectable cytotoxic drugs was valued at USD 9.7 billion in 2023 and is anticipated to showcase 5.8% CAGR from 2024
Why is the demand for antimetabolites rising?
Why is the injectable cytotoxic drugs industry booming in North America?
Who are the major global injectable cytotoxic drugs industry players?
Injectable Cytotoxic Drugs Market Scope

Report Content

Chapter 1   Methodology & Scope

1.1    Market scope & definitions

1.2    Research design

1.2.1    Research approach

1.2.2    Data collection methods

1.3    Base estimates & calculations

1.3.1    Base year calculation

1.3.2    Key trends for market estimation

1.4    Forecast model

1.5    Primary research and validation

1.5.1    Primary sources

1.5.2    Data mining sources

Chapter 2   Executive Summary

2.1    Industry 3600 synopsis

Chapter 3   Industry Insights

3.1    Industry ecosystem analysis

3.2    Industry impact forces

3.2.1    Growth drivers

3.2.1.1    Increasing incidence of cancer and rheumatoid arthritis

3.2.1.2    Growing regulatory approvals for injectable cytotoxic drugs

3.2.1.3    Increasing investments for the development of precision oncology therapies

3.2.1.4    Rapid increase in cancer care facilities

3.2.2    Industry pitfalls & challenges

3.2.2.1    High drug development cost

3.2.2.2    Presence of strong alternative therapies

3.3    Growth potential analysis

3.4    Future market trends

3.5    Regulatory landscape

3.6    Porter's analysis

3.7    PESTEL analysis

Chapter 4   Competitive Landscape, 2023

4.1    Introduction

4.2    Company market share analysis

4.3    Company matrix analysis

4.4    Competitive positioning matrix

4.5    Strategy dashboard

Chapter 5   Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)

5.1    Key trends

5.2    Antimetabolites

5.3    Vinca alkaloids

5.4    Taxanes

5.5    Anthracyclines

5.6    Platinum compounds

5.7    Alkylating agents

5.8    Other drug classes

Chapter 6   Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)

6.1    Key trends

6.2    Hospital pharmacies

6.3    Retail pharmacies

6.4    Online pharmacies

Chapter 7   Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)

7.1    Key trends

7.2    Oncology

7.3    Rheumatoid arthritis

7.4    Multiple sclerosis

7.5    Other applications

Chapter 8   Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)

8.1    Key trends

8.2    North America

8.2.1    U.S.

8.2.2    Canada

8.3    Europe

8.3.1    Germany

8.3.2    UK

8.3.3    France

8.3.4    Spain

8.3.5    Italy

8.3.6    Netherlands

8.3.7    Rest of Europe

8.4    Asia Pacific

8.4.1    China

8.4.2    Japan

8.4.3    India

8.4.4    Australia

8.4.5    South Korea

8.4.6    Rest of Asia Pacific

8.5    Latin America

8.5.1    Brazil

8.5.2    Mexico

8.5.3    Rest of Latin America

8.6    Middle East and Africa

8.6.1    South Africa

8.6.2    Saudi Arabia

8.6.3    UAE

8.6.4    Rest of Middle East and Africa

Chapter 9   Company Profiles

9.1    Abbvie Inc

9.2    Accord Healthcare, Inc.

9.3    Amgen, Inc.

9.4    Baxter International Inc.

9.5    Bristol-Myers Squibb Company

9.6    Eli Lilly and Company

9.7    F. Hoffmann-La Roche Ltd.

9.8    Fresenius Kabi AG

9.9    Johnson and Johnson Services Inc.

9.10    Merck & Co. Inc.

9.11    Novartis AG

9.12    Pfizer, Inc.

9.13    Sanofi

9.14    Takeda Pharmaceutical Company Limited

9.15    Teva Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani
Buy Now
$4,123 $4,850
15% off
$4,280 $5,350
20% off
$5,845 $8,350
30% off
    Buy now
Premium Report Details

Base Year: 2023

Companies covered: 15

Tables & Figures: 218

Countries covered: 22

Pages: 119

Download Free Sample

Top